Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients

Publication

Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients

Journal Paper/Review - Dec 8, 2019

Olearo Flaminia, D'arminio Monforte Antonella, Zazzi Maurizio, Rossetti Barbara, Neau Didier, Bellecave Pantxika, Rijnders Bart, Reiss Peter, Wit Ferdinand, Kouyos Roger, Boeni Jürg, Bernasconi Enos, Günthard Huldrych F, Nguyen Huyen, Bonnet Fabrice, Yerly Sabine, Wandeler Gilles, Stoeckle Marcel, Cavassini Matthias, Scherrer Alexandra, Costagliola Dominique, Schmid Patrick, Calmy Alexandra

Citation

Olearo F, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Boeni J, Bernasconi E, Günthard H, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagliola D, Schmid P, Calmy A. Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. Open Forum Infect Dis 2019; 6:ofz500.

Type

Journal Paper/Review (English)

Journal

Open Forum Infect Dis 2019; 6

Publication Date

Dec 8, 2019

Issn Print

2328-8957

Pages

ofz500

Brief description/objective

[This corrects the article DOI: 10.1093/ofid/ofz330.][This corrects the article DOI: 10.1093/ofid/ofz330.].